Results of recent in vitro studies of aminoglycoside drugs demonstrate that nonsense CDKL5 variants are efficiently suppressed, raising the question of utility of ataluren for CDD [39]. The gene discussed is CDKL5; the disease is craniodiaphyseal dysplasia.